| Vol. 12.46 – 24 November, 2020 |
| |
|
|
| Smurf2 induced the ubiquitination of Smad1/5. Bone morphogenetic protein (BMP)/Smad signaling was enhanced in Smurf2−/− bone marrow stromal cells (BMSCs) stimulated with recombinant human BMP2, and the inhibition of BMP/Smad signaling suppressed osteogenic differentiation of these BMSCs. [Bone Research] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Scientists investigated the molecular mechanisms by which MSC3D gained the potential for enhanced cell viability. They found that macroautophagy/autophagy was highly induced and ROS production was suppressed in MSC3D as compared to 2D-cultured MSCs. [Autophagy] |
|
|
|
| Investigators successfully isolated chondrogenic-extracellular vesicles (C-EVs) from human multi-finger cartilage and found that C-EVs efficiently promoted the proliferation and chondrogenic differentiation of human umbilical cord MSCs, evidenced by highly expressed aggrecan, COL2A, and SOX-9. [Journal of Nanobiotechnology] |
|
|
|
| MSCs isolated from bone marrow of wild type and Sdc3−/− mice were used to assess immunophenotype, differentiation, adhesion and migration properties and cell signaling pathways. [Scientific Reports] |
|
|
|
| Researchers assessed a novel cyclical aggregation as a means of expanding MSCs to maintain stem cell functionality. The cyclical aggregation consisted of an aggregation phase and an expansion phase by replating the dissociated MSC aggregates onto planar tissue culture surfaces. [Scientific Reports] |
| |
|
|
| Scientists evaluated if human MSCs from both fetal and adult tissues constitutively expressed angiotensin‐converting enzyme 2 (ACE2) and type II transmembrane serine protease (TMPRSS2) and, most importantly, if they could be infected by SARS‐CoV‐2. [Stem Cells Translational Medicine] |
|
|
|
| Researchers injected either umbilical cord MSCs or saline to the full-thickness rotator cuff defect and investigated macroscopic, histological and biomechanical results and cell trafficking. [PLoS One] |
|
|
|
| The authors confirmed that the mechanical properties of hydrogel enhanced by the introduction of metal ions Fe3+ could promote MSC proliferation, induce cartilage-specific gene expression, and increase secretion of hydroxyproline and glycosaminoglycan. [International Journal of Biological Macromolecules] |
|
|
|
| Functional studies using CRISPR-Cas9 gene-edited cells demonstrated a key role for the TSC2/RHEB axis in regulating TGF-β1-induced mechanistic target of rapamycin complex 1 activation and collagen I deposition in mesenchymal cells reflecting idiopathic pulmonary fibrosis and other disease settings, including cancer-associated fibroblasts. [Thorax] |
|
|
|
| Following Treg depletion, the function and phenotype of both MSCs and hematopoietic stem cells was impaired. Transplantation also revealed that a Treg-depleted niche had a reduced capacity to support hematopoiesis. [JCI Insight] |
|
|
|
|
| Scientists review the potential mechanism of stem cells as new therapeutic agents in the treatment of diabetic nephropathy (DN). They also review recent findings and updated information about not only the utilization of stem cells on DN in both preclinical and clinical trials but limitations and future expectations of stem cell-based therapy for DN. [Cell Death & Disease] |
|
|
|
| The potential for MSC therapy in COVID-19 ARDS is discussed with insights from respiratory viral models and early clinical reports of MSC therapy in COVID-19. [Expert Review of Respiratory Medicine] |
|
|
|
|
| TRACON Pharmaceuticals, Inc. announced its corporate partners, Alphamab Oncology and 3D Medicines, have submitted a new drug application for the approval of envafolimab in the indication of MSI-H/dMMR cancer to the National Medical Products Administration (NMPA). Envafolimab, a subcutaneous PD-L1 single-domain antibody, is being developed in a registration trial for the treatment of sarcoma. [TRACON Pharmaceuticals, Inc.] |
|
|
|
| The Texas Heart Institute has been selected as one of up to 60 sites in the world to participate in an international investigative study seeking to aid COVID-19 patients who develop acute respiratory distress syndrome (ARDS). [Texas Heart Institute] |
|
|
|
|
| April 9 – April 14, 2021 Washington, DC, United States |
|
|
|
|
|
| GSK – Waltham, Massachusetts; Collegeville, Pennsylvania, United States |
|
|
|
| University of Illinois at Chicago College of Medicine – Chicago, Illinois, United States |
|
|
|
| Stanford University – Stanford, California, United States |
|
|
|
| Oklahoma Medical Research Foundation – Oklahoma City, Oklahoma, United States |
|
|
|
| Zhejiang University-University of Edinburgh Institute – Haining, China |
|
|
|
|